Put Options

16 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$124.33 - $156.75 $621,650 - $783,750
5,000 New
5,000 $624,000
Q1 2024

May 15, 2024

BUY
$93.7 - $141.53 $468,500 - $707,650
5,000 New
5,000 $647,000
Q3 2021

Nov 09, 2021

SELL
$65.97 - $92.48 $145,134 - $203,456
-2,200 Reduced 27.5%
5,800 $536,000
Q3 2020

Nov 12, 2020

SELL
$127.12 - $172.34 $3.05 Million - $4.14 Million
-24,000 Reduced 75.0%
8,000 $1.12 Million
Q2 2020

Aug 12, 2020

SELL
$93.0 - $171.7 $9.9 Million - $18.3 Million
-106,500 Reduced 76.9%
32,000 $5.13 Million
Q1 2020

May 13, 2020

SELL
$82.38 - $131.64 $280,092 - $447,575
-3,400 Reduced 2.4%
138,500 $13.5 Million
Q4 2019

Feb 10, 2020

BUY
$76.53 - $135.58 $3.61 Million - $6.4 Million
47,200 Added 49.84%
141,900 $18.3 Million
Q3 2019

Nov 14, 2019

SELL
$72.81 - $156.91 $5.18 Million - $11.2 Million
-71,200 Reduced 42.92%
94,700 $7.13 Million
Q2 2019

Aug 14, 2019

SELL
$112.21 - $151.95 $493,724 - $668,580
-4,400 Reduced 2.58%
165,900 $25.2 Million
Q1 2019

May 15, 2019

BUY
$106.67 - $151.68 $12.4 Million - $17.6 Million
116,000 Added 213.63%
170,300 $20.3 Million
Q4 2018

Feb 14, 2019

BUY
$97.32 - $148.76 $1.94 Million - $2.96 Million
19,900 Added 57.85%
54,300 $5.93 Million
Q3 2018

Nov 14, 2018

SELL
$115.31 - $161.51 $6.72 Million - $9.42 Million
-58,300 Reduced 62.89%
34,400 $5.56 Million
Q2 2018

Aug 14, 2018

BUY
$71.74 - $153.69 $4.31 Million - $9.24 Million
60,100 Added 184.36%
92,700 $12.3 Million
Q1 2018

May 15, 2018

SELL
$54.02 - $82.27 $9.98 Million - $15.2 Million
-184,700 Reduced 85.0%
32,600 $2.42 Million
Q4 2017

Feb 14, 2018

BUY
$47.64 - $56.75 $5.65 Million - $6.73 Million
118,600 Added 120.16%
217,300 $12.1 Million
Q3 2017

Nov 14, 2017

BUY
$35.73 - $47.15 $3.53 Million - $4.65 Million
98,700
98,700 $4.48 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.4B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.